Clinical TrialJun 18, 2026, 08:32 AM
MAIA Biotechnology Activates 3rd US Clinical Site for THIO-101 Trial
AI Summary
MAIA Biotechnology announced the activation of Winship Cancer Institute of Emory University as the third U.S. clinical site for its Phase 2 THIO-101 expansion trial, which is now enrolling patients. The trial evaluates ateganosine as a third-line treatment for non-small cell lung cancer (NSCLC) in patients resistant to checkpoint inhibitors and chemotherapy. Winship is Georgia's only NCI-designated Comprehensive Cancer Center, and early efficacy data from Parts A and B of the trial have shown promising results, with some patients surviving over two years.
Key Highlights
- MAIA Biotechnology activated Winship Cancer Institute of Emory University as the third U.S. clinical site for its Phase 2 THIO-101 expansion trial.
- The trial is now enrolling patients for ateganosine as a third-line (3L) treatment for non-small cell lung cancer (NSCLC).
- Winship Cancer Institute is Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center.
- THIO-101 is an ongoing Phase 2, open-label trial evaluating ateganosine followed by cemiplimab for NSCLC patients.
- Parts A and B of the trial have shown strong early efficacy, with some patients exceeding two years of survival.
- Ateganosine is a first-in-class investigational telomere-targeting agent.
- Lung cancer is the leading cause of cancer-related deaths in Georgia, with over 7,300 new cases in 2025.
Price Impact
More from MAIA